Skip to content

Advertisement

  • Research article
  • Open Access

Accumulation of amyloid-β by astrocytes result in enlarged endosomes and microvesicle-induced apoptosis of neurons

  • 1,
  • 1,
  • 1,
  • 2,
  • 1,
  • 1 and
  • 1Email author
Molecular Neurodegeneration201611:38

https://doi.org/10.1186/s13024-016-0098-z

©  Söllvander et al. 2016

  • Received: 22 October 2015
  • Accepted: 15 April 2016
  • Published:

Abstract

Background

Despite the clear physical association between activated astrocytes and amyloid-β (Aβ) plaques, the importance of astrocytes and their therapeutic potential in Alzheimer’s disease remain elusive. Soluble Aβ aggregates, such as protofibrils, have been suggested to be responsible for the widespread neuronal cell death in Alzheimer’s disease, but the mechanisms behind this remain unclear. Moreover, ineffective degradation is of great interest when it comes to the development and progression of neurodegeneration. Based on our previous results that astrocytes are extremely slow in degrading phagocytosed material, we hypothesized that astrocytes may be an important player in these processes. Hence, the aim of this study was to clarify the role of astrocytes in clearance, spreading and neuronal toxicity of Aβ.

Results

To examine the role of astrocytes in Aβ pathology, we added Aβ protofibrils to a co-culture system of primary neurons and glia. Our data demonstrates that astrocytes rapidly engulf large amounts of Aβ protofibrils, but then store, rather than degrade the ingested material. The incomplete digestion results in a high intracellular load of toxic, partly N-terminally truncated Aβ and severe lysosomal dysfunction. Moreover, secretion of microvesicles containing N-terminally truncated Aβ, induce apoptosis of cortical neurons.

Conclusions

Taken together, our results suggest that astrocytes play a central role in the progression of Alzheimer’s disease, by accumulating and spreading toxic Aβ species.

Keywords

  • Alzheimer’s disease
  • Protofibrils
  • Glia
  • Phagocytosis
  • Degradation
  • Enlarged vacuole
  • Microvesicle

Background

Knowledge about the cellular mechanisms behind initiation and spreading of Alzheimer’s disease (AD) is still very limited. Decades of research have focused on neuronal abnormalities in AD pathology, but recently more attention has been given to other cell types, including astrocytes [1]. Being the most abundant glial cell type in the nervous system, astrocytes are highly responsible for maintaining brain homeostasis [2]. Their functions include metabolic support of neurons, modification of synapse signaling, recycling of neurotransmittors, regulation of blood flow and contribution to the blood brain barrier [2, 3]. In addition, astrocytes respond to all pathological conditions through a process referred to as reactive astrogliosis, in which the astrocytes convert to an inflammatory state [4].

The amyloid cascade hypothesis suggests that amyloid-β (Aβ) mis-metabolism is the main causative event in AD, from which all other neuropathological features emanate [5]. Due to its hydrophobic nature, Aβ monomers will aggregate and form soluble aggregated species, which eventually deposit as senile plaques. A major concern with the amyloid cascade hypothesis is that the number of plaques does not correlate with the severity of dementia [6, 7]. However, results from different research groups indicate that it is the presence of soluble Aβ aggregates, such as oligomers and protofibrils, rather than the plaques that induces the widespread neuronal death [8–12]. Protofibrils have been shown to be the predominant species of soluble Aβ aggregates in both tg-ArcSwe mice and human AD brains [13, 14]. Moreover, the levels of soluble Aβ aggregates in cerebrospinal fluid (CSF) have been demonstrated to be elevated in AD patients compared to controls and to correlate with cognitive impairment [15–18].

There is compelling evidence that Aβ pathology is closely associated with inflammation and reactive astrocytes and microglia are situated tightly around the plaques [19]. The formation of a glial capsule around the Aβ deposits may protect the surrounding brain tissue from toxic Aβ species, but the astrocytes and microglia have also been shown to secrete cytokines and neurotoxic products that could induce neuronal degeneration [20]. Astrocytes effectively engulf dead cells, synapses and protein aggregates of Aβ and α-synuclein [21–27]. Interestingly, astrocytes have been shown to be more efficient than microglia in taking up Aβ, particularly during the early stages of AD [28]. The fact that reactive astrocytes with high Aβ load are frequently found in the AD brain further confirms the importance of astrocytes in Aβ clearance [29]. Compared to macrophages, that start to digest phagocytosed cell corpses directly, our group has previously demonstrated that it takes almost two weeks for astrocytes to degrade ingested, dead cells [26]. The inefficient degradation of dead cells by astrocytes is at least partly due to long lasting actin-rings surrounding the phagosomes, physically inhibiting the phagosome-lysosome fusion [30]. It is known that a large phagocytic burden could also inhibit degradation in professional phagocytes, by prolonging the time actin surrounds the phagosome [31]. Further, the astrocytes express high levels of Rab27a, a protein that reduces the lysosome acidity [30].

Since the majority of the patients with sporadic AD do not have an increased Aβ production, it has been suggested that the main cause of this form of the disease is instead insufficient lysosomal degradation [32, 33]. Moreover, it is known that patients with lysosomal storage disorders often develop neurodegenerative diseases, including AD and Parkinson’s disease [32, 34]. Ineffective degradation of Aβ may lead to spreading of AD pathology, due to secretion of Aβ-containing vesicles [35]. We hypothesized that astrocytes, due to their ineffective digestion may be an important player in these processes and the aim with the present investigation was to elucidate the role of astrocytes in Aβ42 protofibril clearance and toxicity. Our data demonstrates that astrocytes engulf large amounts of Aβ42 protofibrils that are stored in the astrocytes for a long time, rather than being degraded. This intracellular accumulation causes severe endosomal/lysosomal defects that probably reduce the degradation capacity of the astrocytes further. In addition, incomplete degradation of Aβ42 protofibrils results in microvesicle-induced neurotoxicity. Taken together, our results indicate that slow degradation by astrocytes may be a key process in Aβ pathology.

Results

Astrocytes engulf large amounts of Aβ42 protofibrils

In order to investigate the uptake of Aβ42 protofibrils by the major cell types in the brain, we performed experiments using co-cultures of cortical astrocytes, neurons and oligodendrocytes. The cell cultures were exposed to fluorescent HiLyte™ Fluor 555-labeled Aβ42 (Aβ42-555) protofibrils for 24 h, fixed and stained with specific antibodies to Glial Fibrillary Acidic Protein (GFAP), βIII tubulin and 2',3'-Cyclic-nucleotide 3'-phosphodiesterase (CNPase), to label astrocytes, neurons and oligodendrocytes, respectively. We found that astrocytes contained large amounts of Aβ42-555 (Fig. 1a and Additional file 1), while almost no Aβ42-555 could be detected in the neurons (Fig. 1b and Additional file 1). Interestingly, the Aβ42-555 inclusions in the astrocytes frequently co-localized with condensed, terminal (TdT)-mediated dUTP-biotin (TUNEL) positive cell nuclei of dead cells that had also been engulfed by the glial cells (Fig. 1a and Additional file 2). Uptake of Aβ42-555 protofibrils was also noted in the oligodendrocytes (Fig. 1c). However, the approximate percentage of oligodendrocytes in the cultures is very low (6 % ± 3), compared to the astrocytes (75 % ± 8) and neurons (25 % ± 8). To confirm that the Aβ42-555 deposits were situated inside the astrocytes we used confocal microscopy. The 3D-images clearly show that Aβ42-555 protofibrils were taken up and predominantly localized around condensed nuclei of dead cells inside the astrocytes (Fig. 1d and Additional file 3). It is important to remember that GFAP stains the cytoskeleton of the astrocyte, which only constitutes 15–20 % of the cell [36]. Hence, the whole astrocyte is much bigger than the GFAP staining and the Aβ42-555 found close to the GFAP staining is most likely also situated inside the cell (Fig. 1d and Additional file 3).
Fig. 1
Fig. 1

Aβ42 protofibril deposits are found in glial cells, but not in neurons. Immunocytochemistry of co-cultures containing astrocytes, neurons and oligodendrocytes demonstrates that astrocytes contain large deposits of Aβ42-555 (a). Neurons lack detectable Aβ42-555 levels (b), but the few oligodendrocytes in the culture also contain Aβ42-555 (c). Confocal imaging confirms intracellular localization of large Aβ42-555 inclusions in astrocytes (d). DAPI (blue), GFAP (green) and Aβ42-555 (red). Scale bars: a–c = 20 μm, d = 10 μm

To verify that the 555-label still bound to the Aβ after the engulfment, parallel co-cultures were treated with unlabeled Aβ42 protofibrils for 24 h, fixed and stained with GFAP and four different Aβ antibodies; mAb1C3 and 6E10 (both binding to the N-terminus of Aβ), mAb158 (selective for Aβ protofibrils) and a polyclonal Aβ42 antibody. All antibodies displayed similar staining pattern, as received with the Aβ42-555 protofibrils, demonstrating that the 555-signal represents the presence of Aβ (Additional file 4 A-D). To exclude that the degradation of Aβ42 protofibrils in astrocytes was influenced by the neurons present in the co-culture, we performed experiments with cell cultures differentiated in the presence of cilliary neurotrophic factor (CNTF). CNTF is known to drive E14 neural stem cells to generate almost exclusively astrocytes [37, 38]. The astrocytes in the CNTF-treated cultures were found to accumulate Aβ42 protofibrils in a similar way to those in the co-cultures (Additional file 5). To follow the engulfment of Aβ protofibrils over time we next performed time-lapse experiments, in which we recorded the cell culture during the 24 h Aβ42-555 protofibril exposure. Our time-lapse movies demonstrate that already after 30 min, astrocytes (identified by their phenotype of an egg “sunny side up”, large nuclei and multi-vesicular cytoplasm) had accumulated Aβ42-555, and the intensity of the staining constantly increased during the 24 h time period (Fig. 2a, b and Additional file 6). In line with our results from the immunostainings, very little of the Aβ42-555 protofibrils co-localized with neurons (identified by their oval cell bodies, distinct axons and active migration) (Fig. 2a, c and Additional file 6).
Fig. 2
Fig. 2

Aβ42 protofibrils accumulate intracellulary in astrocytes over time. Time-lapse images from 30 min to 24 h following Aβ42-555 protofibril administration show that astrocytes (A), but not neurons (*), accumulate Aβ42-555 over time (a). Higher magnification of a highly vascularized astrocyte with ingested Aβ42-555 (b) and a neuron with undetectable levels of intracellular Aβ42-555 (c). Immunohistochemistry of tg-ArcSwe mouse brain sections confirm that Aβ plaques are surrounded by GFAP positive astrocytes, Aβ (red), GFAP (green) and DAPI (blue) (d) and that Aβ are engulfed by astrocytes in vivo (e). Scale bars: a–d = 10 μm

The tg-ArcSwe mouse model is known to have elevated levels of soluble Aβ aggregates including protofibrils, and AD-like Aβ plaque pathology with an onset around six months of age [39–41]. Immunostainings of brain sections from 12 to 14-month-old tg-ArcSwe mice, using antibodies against GFAP and Aβ demonstrated that astrocytes, as expected, were tightly localized around Aβ plaques (Fig. 2d) and that Aβ co-localize with astrocytes in vivo (Additional file 7). Interestingly, we also found that some of the Aβ that had been ingested by reactive astrocytes co-localized with condensed nuclei of dead cells, confirming that our findings in the cell cultures reflect cellular processes of Aβ pathology in vivo (Fig. 2e).

Aβ protofibrils are accumulated in astrocytes for a very long time

To follow the degradation of intracellular Aβ42 protofibrils in astrocytes, neurons and oligodendrocytes, cell cultures were thoroughly washed after the 24 h Aβ42-555 protofibril exposure and cultured for additional 6 or 12 days prior to fixation and staining. The cells were divided into four categories; cells with no detectable levels of Aβ42-555 (−), cells with only small amounts of Aβ42-555 (+), cells containing medium sized Aβ42-555 inclusions or larger Aβ42-555 inclusions with low intensity (++) and cells with one or more large Aβ42-555 inclusion with high intensity (+++). The four categories in combination with GFAP staining are shown in Fig. 3a. Quantification of the percentage of astrocytes in each category demonstrates that most astrocytes contained large inclusions of Aβ42-555 (+++) directly after the 24 h exposure (63.5 ± 20.1 %). Although the percentage of (+++) astrocytes had decreased significantly after 6 days (30.7 ± 24.0 %, P < 0.001) and 12 days (33.8 ± 15.3 % P < 0.001), the degradation was extremely slow. The percentage of astrocytes containing medium sized Aβ42-555 inclusions (++) was lower at 24 h (15.4 ± 11.0 %), but did not decrease over time. Astrocytes containing small amounts of Aβ42-555 (+) and astrocytes with no detectable levels of Aβ42-555 (−) increased significantly from 24 h (18.3 ± 16 % respective 2.6 ± 4.6 %) to 24 h + 6 days (30.0 ± 16.6 %, P = 0.0034 respective 22.6 ± 18.8 %, P < 0.001). Taken together, these results demonstrate that astrocytes effectively ingest Aβ42 protofibrils, but that the ingested material is only partially degraded within 12 days (Fig. 3b). Neurons had low or no detectable Aβ42-555 inclusions at 24 h (Fig. 3c) whereas most of the few oligodendrocytes in the culture contained large (+++) or medium (++) Aβ42-555 inclusions that did not significantly change over time (Fig. 3d). As a complement, we next analyzed the total number of inclusions, total intensity and total area of Aβ42-555 deposits (normalized to the total number of cells) in the cell culture, using the Zen 2012 software. The number of 555-stained inclusions, normalized to the number of live cell nuclei, declined significantly from 24 h to 24 h + 6 days (P < 0.001), indicating that the inclusions were either degraded or fused (Fig. 3e). The total 555-intensity (Fig. 3f) and total 555-positive area (Fig. 3g) also declined significantly over time (P < 0.001 already from 24 h to 24 h + 6 days), confirming that the astrocytes degrade the Aβ42-555 protofibrils to some degree, although very slowly. In contrast to our results with Aβ42-555 protofibrils, cell cultures exposed to Aβ40-555 monomers, showed no accumulation of Aβ in astrocytes (Additional file 8).
Fig. 3
Fig. 3

Aβ42 are stored in astrocytes for a very long time. To follow degradation of intracellular Aβ42-555 in astrocytes following Aβ42-555 protofibril removal, cells were divided into four categories; cells with no detectable levels of Aβ42-555 (–), cells with only small amounts of Aβ42-555 (+), cells containing medium sized Aβ42-555 deposits (++) and cells with large Aβ42-555 inclusions (+++) (a). Astrocytes degrade Aβ42-555 protofibrils very slowly and much Aβ42 remains in the cells 12 days after Aβ42-555 protofibril removal (b). Neurons contain almost no Aβ42 (c). The few oligodendrocytes in the culture also degrade the Aβ42-555 protofibrils slowly (d). Although the glial cells degrade the Aβ42-555 protofibrils slowly, the total number of 555-stained inclusions (24 h: 10.4 ± 7.7; 24 h + 6 days: 7.9 ± 7.1; 24 h + 12 days: 6.2 ± 7.1) in the culture decline significantly from 24 h to 24 h + 6 days (P = 0.013) and 24 h + 12 days (P < 0.001) (e). In line with these results, the total 555-intensity (24 h: 1.7 × 107 ± 8.5 × 106; 24 h + 6 days: 8.3 × 106 ± 5.1 × 106; 24 h + 12 days: 5.9 × 106 ± 4.3 × 106) (f) and total 555-positive area (24 h: 9.6 ± 2.3 μm2; 24 h + 6 days: 6.7 ± 3.5 μm2; 24 h + 12 days: 6.8 ± 2.5 μm2) (g) also decline significantly over time (P < 0.001 already from 24 h to 24 h + 6 days). Aβ inclusions are marked with white arrow heads. Scale bars: 10 μm. The experiments were performed in triplicates with independent cell cultures and 10 images/experiment were analyzed. Mann–Whitney U-test ***P < 0.001

Engulfed Aβ protofibrils co-localize with the lysosomal marker LAMP-1

In order to investigate the intracellular localization of the Aβ deposits in astrocytes we next performed immunostainings with the lysosome specific antibody LAMP-1. Our results show that there was only little overlap between LAMP-1 and Aβ42 directly after the Aβ42 protofibril exposure (24 h), but the co-localization increased over time and 12 days after Aβ42 protofibril removal, most of the intracellular Aβ42 deposits co-localized with LAMP-1 positive vesicles (Fig. 4a). These results demonstrate that the engulfed Aβ42 protofibrils were transported to lysosomal compartments within the astrocytes. However, we have previously shown that engulfed dead cells in astrocytes can be present in LAMP-1 positive phagosomes/lysosomes without being degraded. The reason is insufficient acidification of astrocytic lysosomes resulting in inadequate digestion of the ingested material [26]. To clarify if the lysosomes in the Aβ42 protofibril accumulating astrocytes were acidic or not, we performed experiments using LysoTracker, which is a dye that labels acidic organelles. We found that although being LAMP-1 positive, the Aβ42 containing lysosomes did not stain with the LysoTracker, indicating that Aβ42 stored in the glial cells were situated in immature lysosomes (Fig. 4b). Interestingly, immunostainings of brain sections from 14-month-old tg-ArcSwe mice using specific antibodies against LAMP-2 and mAb158 (Fig. 4c) or GFAP and mAb158 (Fig. 4d) demonstrated that Aβ co-localized with both LAMP-2 and GFAP in vivo. It was the outermost layer of the Aβ plaque, rather than the plaque core that was LAMP-2 positive, suggesting that the most superficial Aβ could actually be situated in lysosomal compartments inside the glial cells that tightly surround the plaque (as GFAP only stains 15–20 % of the astrocytic cell bodies [36]).
Fig. 4
Fig. 4

Aβ42 accumulates in immature lysosomes. The co-localization of Aβ42 and LAMP-1 positive lysosomes increases from 24 h to 24 h + 12 days (a). LysoTracker staining does not overlap with the Aβ42 protofibril inclusions, demonstrating that the Aβ42 containing lysosomes are immature (b). Aβ42 protofibrils co-localize with LAMP-2 (c) and GFAP (d) in sections of 14-month-old tg-ArcSwe mice. Scale bars: a–d = 20 μm

Intracellular stored Aβ is truncated in the N-terminus

We next sought to investigate if the Aβ42 stored in the immature lysosomes was partly degraded. For this purpose we analyzed cell culture lysates using three different sets of sandwich ELISAs; the N-terminus dependent Aβ1-x ELISA, the protofibril specific mAb158 ELISA and the N-terminus independent Aβx-42 ELISA. In the Aβ1-x ELISA, one of the antibodies is specific for the N-terminal Aβ neo-epitope (82E1, raised against Aβ1-16) and the other antibody binds to the central region of Aβ (4G8, raised against Aβ17-24), measuring Aβ42 with an intact N-terminal. In the Aβx-42 ELISA, one of the antibodies is specific for the C-terminal Aβ42 neo-epitope [42] and the other antibody binds to the central region of Aβ (4G8), measuring both intact and N-terminally truncated forms of Aβ. Both the Aβ1-x ELISA and the mAb158 ELISA, showed a 3-fold decrease in Aβ concentrations from 24 h to 24 h + 6 days (P < 0.001 for both) (Fig. 5a, b). The Aβ levels measured by the Aβ1-x ELISA decreased further and were halved at 24 h + 12 days compared to 24 h + 6 days (P = 0.0058) (Fig. 5a). In contrast, when analyzing the cell lysates using the Aβx-42 ELISA, the concentrations did not decrease during the first 6 days and there was only a 1.5-fold decline from 24 h + 6 days to 24 h + 12 days (P = 0.036). Hence, the concentrations remained higher using the Aβx-42 ELISA compared to the Aβ1-x and mAb158 ELISA, indicating that a high proportion of the stored Aβ is N-terminally truncated (Fig. 5a–c). Since our immunostainings demonstrated that the engulfed Aβ often co-localized with condensed cell nuclei of dead cells that had also been ingested by the astrocytes (Fig. 1a), we performed additional analysis of the pellet (consisting of nuclei and cell debris) that remained after the cell lysis procedure. The pellets were treated with formic acid and sonication to extract Aβ prior to analysis with the Aβ1-x ELISA and the Aβx-42 ELISA. Interestingly, we found that the pellet fraction from 24 h, but also from 24 h + 6 days and 24 h + 12 days showed higher Aβ concentrations in the Aβx-42 ELISA compared to the Aβ1-x ELISA, indicating existence of N-terminally truncated Aβ42 (Fig. 5d, e). Taken together, the results show that full length Aβ1-42 and Aβ42 protofibrils (Fig. 5a, b, d) decrease more over time than N-terminally truncated forms of Aβ (Fig. 5c, e), indicating that the intracellular deposits of Aβ in astrocytes are processed by the astrocytes in a way that may change their properties and toxicity.
Fig. 5
Fig. 5

Intracellular stored Aβ42 is truncated in the N-terminus. Aβ ELISAs of cell lysates from 24 h and from 6 to 12 days following Aβ42 protofibril removal (24 h + 6 days and 24 h + 12 days, respectively) demonstrate that a high proportion of the accumulated Aβ is N-terminally truncated. The concentrations of Aβ1-x (a) and Aβ protofibrils (b) decrease continuously from 24 h (2434.0 ± 272.0 and 946.9 ± 36.5, respectively) to 24 h + 6 days (862.8 ± 92.0 and 325.8 ± 25.9, respectively) and 24 h + 12 days (468.2 ± 52.2 and 282.9 ± 13.1, respectively), while the concentrations of Aβx-42 remain higher over time (24 h: 2475.0 ± 134.0, 24 h + 6 days: 226.01 ± 318.3 and 24 h + 12 days: 1531.0 ± 253.1) (c). In the pellets, remaining after the cell lysis procedure, the Aβ1-x concentrations decline over time (24 h: 1840.0 ± 289.5, 24 h + 6 days: 938.3 ± 159.7, 24 h + 12 days: 483.3 ± 225.3) (d), while the Aβx-42 concentrations are higher at 24 h (2422.0 ± 387.0) and more stable over time, 24 h + 6 days (1493.0 ± 132.7) and 24 h + 12 days (1488.0 ± 312.6) (e). All concentrations are expressed in picomolar (pM) units. Mean values are from duplicates of three independent experiments

Aβ accumulation induces formation of giant astrocytic endosomes

The cell cultures were followed for up to 5 days after the Aβ42 protofibril exposure, using time-lapse recordings. Interestingly, we found that the accumulation of Aβ42 protofibrils induced formation of enlarged, dynamic vacuoles in the astrocytes (Fig. 6a, and Additional file 9). The vacuoles increased rapidly in size, fused with adjacent vacuoles and resulted in giant vacuoles with a diameter of ~50 μm (Fig. 6b, and Additional file 10). The giant vacuoles eventually shrank or collapsed, but concurrently new vacuoles appeared in the same cell (Fig. 6a, and Additional file 9). The enlarged vacuoles were never found in control cultures, indicating that they are a direct result of the high Aβ42 load in the astrocytes. Immunostainings of fixed, Aβ42 protofibril exposed cell cultures, using specific antibodies to the early endosomal marker, Rab5, and the late endosomal marker, Rab7, demonstrated that the giant vacuoles are proposed to be derived from early endosomes (Fig. 6c). Moreover, double stainings with specific antibodies to Aβ/Rab5 and Aβ/Rab7 (Additional file 11), showed a clear co-localization of Aβ inclusions and Rab5. Some co-localization was also noted for Aβ and Rab7. These data emphasize that accumulation of Aβ42 protofibrils induces severe lysosome failure in the phagocytic astrocytes. The collapsing vacuoles did not cause astrocytic cell death during the time-lapse experiment, but may induce the release of Aβ containing microvesicles from the astrocytes.
Fig. 6
Fig. 6

Aβ42 protofibril treatment results in formation of enlarged endosomes. Time-lapse experiments demonstrate that Aβ42 protofibril treatment induces the formation of enlarged, dynamic vacuoles (*) in the astrocytes (a). The enlarged vacuoles fuse (white arrow heads) with adjacent vacuoles; forming giant vacuoles with a diameter of 30–50 μm (b). Immunocytochemistry show that the vacuoles express the early endosome marker Rab5 and to a lesser extent the late endosome marker Rab7 (c). Inset in left corner of image c shows higher magnification of relevant structure. Scale bars: a–b = 10 μm, c = 20 μm

Engulfing astrocytes induce secondary Aβ toxicity

To further investigate how the Aβ42 protofibril exposure affects viability of the three different cell types in the culture, we quantified the number of living astrocytes, neurons and oligodendrocytes directly after the 24 h Aβ42 protofibril exposure and 6 and 12 days after Aβ42 protofibril removal. The total number of cells was compared to the cell number in parallel control cultures that did not receive any Aβ42 protofibrils. A modest, but significant, increase in the cell number following Aβ42 protofibril exposure was noted at 24 h + 12 days, for both astrocytes and oligodendrocytes (P = 0.011 and P < 0.001, respectively) (Fig. 7a and b), indicating that the Aβ42 protofibril clearing process induces some proliferation of the glial cells. In contrast, the number of neurons was decreasing over time in the Aβ42 protofibril exposed cultures (Fig. 7c). The fact that Aβ42 protofibril exposure did not induce neuronal death directly, but the decrease in neuronal number appeared 12 days after Aβ42 protofibril removal (P = 0.0061), indicates that the cell death is due to a secondary mechanism.
Fig. 7
Fig. 7

Aβ42 protofibril treatment induces secondary neuronal cell death. The number of astrocytes in Aβ42 protofibril exposed cultures is significantly increased from 24 h (1.0 ± 0.1) to 24 h + 12 days (1.1 ± 0.1, P = 0.011) (a). Similar to astrocytes, the number of oligodendrocytes increases from 24 h (0.7 ± 0.3) to 24 h + 12 days (1.7 ± 1.5, P < 0.001) in Aβ42 protofibril treated cultures (b). Aβ42 protofibril treatment has no direct effect on neurons, but the neuronal cell number significantly decreases (from both 24 h, 0.9 ± 0.4, P = 0.0061 and 24 h + 6 days, 1.0 ± 0.4, P = 0.0083) in the treated cultures 12 days (0.7 ± 0.5) after Aβ removal (c). The relative number of viable cells in Aβ42 protofibril exposed cultures is normalized to viable cells in unexposed cultures. The experiments were performed in triplicates with independent cell cultures and 10 images/experiment were analyzed. Mann–Whitney U-test ***P < 0.001

Neuronal cell death is induced by secreted microvesicles

To identify possible mechanisms for the secondary toxicity, we investigated if microvesicles secreted by Aβ42 protofibril treated co-cultures induce apoptosis of cortical neurons. For these experiments we exposed co-cultures with Aβ42 protofibrils for 24 h, washed the cultures thoroughly and cultured the cells in Aβ42 protofibril-free medium for additional 12 days. Parallel control cultures received medium only. Microvesicles were isolated using ultracentrifugation of conditioned medium harvested day 6 and 12 following Aβ42 protofibril removal. The microvesicle pellets were reconstituted in neurobasal medium and added to embryonic cortical mouse neurons that had been cultured for 12 days (12 days in vitro). After 48 h, the neurons were fixed and the number of apoptotic, TUNEL labeled neurons was compared (Fig. 8a). Studies of astrocytes using electron microscopy, demonstrated a release of microvesicles of different sizes (Fig. 8b). Moreover, electron microscopy analysis of the microvesicle preparations, identified microvesicles (>100 nm in diameter, Fig. 8c–d). Microvesicles, isolated from both untreated and Aβ42 protofibril exposed cell cultures, expressed the microvesicle marker Flotillin-1. However, no differences in the total protein concentration of Flotillin-1 was detected between untreated and Aβ42 protofibril exposed cell cultures (Fig. 8e). Interestingly, there was a significant increase in apoptotic neurons in cultures treated with microvesicles from Aβ42 protofibril exposed co-cultures compared to controls (Fig. 8f), demonstrating that Aβ42 protofibril accumulation induces secretion of microvesicles with toxic content. Parallel neuronal cultures, exposed to intact Aβ42 protofibrils, directly added to the medium, showed no difference in the percentage of TUNEL positive cell nuclei or the total number of cell nuclei, compared to untreated cultures (Additional file 12). Since the amount of microvesicles was unchanged (based on the Flotillin-1 expression), the apoptotic effect on neurons was due to the content of the microvesicles. Aβ1-x and Aβx-42 ELISA analysis of microvesicles isolated from the cell culture medium demonstrate that the microvesicles contained primarily an N-terminally truncated form of Aβ42 (Fig. 8g).
Fig. 8
Fig. 8

Neuronal cell death is induced by secreted microvesicles. Illustration of the experimental setup (a). Electron microscopy images of Aβ42 protofibril exposed co-cultures demonstrate microvesicle (*) secretion from a single astrocyte (b) and a larger (c) and smaller (d) microvesicle present in the cell culture medium. Western blot analysis show that the isolated microvesicles express Flotillin-1, but that the levels are unchanged in Aβ42 protofibril treated cultures, compared to controls (e). TUNEL assays demonstrate a significant increase (P < 0.001) in apoptotic neurons following treatment with microvesicles from Aβ42 protofibril exposed co-cultures (465.4 ± 150.4), compared to microvesicles from untreated co-cultures (308.3 ± 109.2) (f). The experiments were performed in triplicates with independent cell cultures and 10 images/experiment were analyzed. Microvesicles isolated from medium collected 6 and 12 days after Aβ42 protofibril exposure contain Aβ as revealed in Aβ1-x (396.9 ± 167.2 pM) and Aβx-42 (1239.0 ± 438.7 pM) ELISA. The Aβ1-x concentration is lower than Aβx-42, indicating that there is a truncation of the Aβ42 N-terminus (g). Duplicate samples from 3 independent experiments were analyzed. Mann–Whitney U-test ***P < 0.001. Scale bars: b = 1 μm, c–d = 100 nm

Discussion

Many studies indicate that the widespread neuronal dysfunction in the AD brain is caused by soluble Aβ aggregates, such as protofibrils, rather than the insoluble fibrils [8–13]. The mechanisms by which Aβ42 protofibrils induce neuronal toxicity is however unclear. It has been suggested that Aβ oligomers promote neuronal cell death, inhibit long-term potentiation and impair synaptic function and plasticity [8, 9, 11, 12, 43–46]. In the present study we show, by using a co-culture system of neurons and glia, that Aβ42 protofibrils are not directly, but indirectly neurotoxic. Extensive engulfment of Aβ42 protofibrils by the astrocytes in the co-culture results in long-term intracellular deposits of Aβ, severe lysosomal dysfunction and formation of N-terminally truncated Aβ that is spread in the co-culture by microvesicle secretion.

Accumulation of Aβ in the AD brain is due to an imbalance between the Aβ production and Aβ clearance. Several studies indicate that monomeric Aβ40 and Aβ42 are degraded by cultured astrocytes following ingestion [47–49]. This conclusion was based on observations that the engulfed Aβ was directly transported to LAMP-positive lysosomes following ingestion [47, 49, 50]. However, neither of the studies confirmed if Aβ degradation actually took place in the lysosomes. We hypothesized that aggregated species of Aβ, such as protofibrils, may be more difficult for the cells to handle than the monomeric form of the protein. Our results show that the degradation of Aβ42 protofibrils in astrocytes is indeed extremely slow, although the ingested Aβ is situated in LAMP-1 phagosomes/lysosomes. Instead, the Aβ42 protofibrils accumulate in the astrocytes, leading to large, intracellular inclusions. In contrast to Aβ42 protofibrils, Aβ40 monomers were not accumulated in the astrocytes, indicating that they are not overall slow degraders. We have previously compared phagocytosis of dead cells by astrocytes and macrophages (which are indistinguishable from activated microglia in the pathological brain) and found that astrocytes in contrast to the professional phagocytes store, rather than degrade ingested dead cells [26, 30]. By using the pHrodo-labeling technique we demonstrated that material ingested by macrophages fuses with mature/acidic lysosomes within 5 h, whereas material engulfed by astrocytes still had not fused with acidic lysosomes after 3 days. Thus, astrocytes are ineffective when it comes to degrading large/toxic material such as cell corpses and protein aggregates. Some reports indicate that astrocytes may be more efficient than microglia in taking up Aβ, particularly during the early stages of AD and astrocytes has been shown to gradually accumulate Aβ throughout cortex in AD patients [28, 29, 51–53]. However, the difference in degradation capacity of the two cell types has not been taken in account in these studies.

Our data show that glial cells, but not neurons accumulate Aβ42 protofibrils. Since the glial cells in our differentiated co-culture system do not die following Aβ exposure, it is unlikely that the noted co-localization of Aβ and dead nuclei is due to phagocytosis of dead Aβ containing cells. Dead cells are however constantly ingested by the astrocytes during the differentiation process, when apoptosis is naturally occurring. These dead cells are then stored in the astrocytes for weeks. Hence, the co-localization is probably due to transportation of the ingested material to the same “garbage dumps” within the astrocytes. Moreover, the ingestion of Aβ is very rapid. Our time-lapse experiments demonstrated that intracellular Aβ-555 deposits are visible already after 30 min (Fig. 2a). Over time the 555-signal of these deposits becomes more and more intense, indicating that the Aβ aggregates are constantly engulfed by the astrocytes and then transported to specific sites within the astrocytes.

In an attempt to identify reasons for the slow digestion of engulfed dead cells in primary astrocytes, we previously found that actin rings surround the phagosomes for long periods of time, which physically inhibit the phago-lysosome fusion [30]. Furthermore, astrocytes express high levels of Rab27a, a protein known to reduce the acidity of lysosomes by Nox2 recruitment, in order to preserve antigens for presentation. We demonstrated that Nox2 co-localizes with the ingested material, indicating that it may influence antigen processing also in astrocytes, as they express MHC class II [30]. By inducing long-time acidification of astrocytic lysosomes using acidic nanoparticles, we could increase the digestion of astrocyte-ingested dead cells. The degradation was, however, normalized over time, indicating that inhibitory pathways are up-regulated in response to the enhanced acidification [30]. By staining the cell cultures with LysoTracker dye in the present study, we also found the lysosomes to be of low acidity, which probably contributes to the incomplete digestion of Aβ. Moreover, the deposition of aggregated Aβ42 in astrocytes results in severe lysosomal dysfunction, including formation of enormous endosomes, indicating that the accumulation of Aβ disturbs the endosome/lysosome machinery. Such enlarged endosomes were never observed in astrocytes storing cell corpses, or cultures exposed to Aβ40 monomers, but only in Aβ42 protofibril accumulating astrocytes. It is likely that this toxic effect of Aβ42 protofibrils affects the astrocytes so that their slow degradation is further reduced.

The fact that the Aβ42 deposits in astrocytes co-localize with the lysosomal marker LAMP-1 indicates that the lysosome function is crucial for Aβ degradation. It is however not excluded that other degradation mechanisms, such as the proteasome machinery could be affected by the presence of toxic Aβ aggregates in the cell. Sections of tg-ArcSwe mice revealed that the Aβ plaques were surrounded by LAMP-2 immunoreactive astrocytes. These findings agree with previous reports of increased LAMP-1 in cerebral cortex of AD patients as the disease progresses [54] and in brains of APPSL-Tg mice during aging [55]. Interestingly, it has been demonstrated that activation of transcription factor EB (TFEB), a regulator of lysosome biogenesis, enhanced uptake and degradation of Aβ in astrocytes, attenuating plaque pathology in APP/PS1 transgenic mice [49]. By studying the lysosomal storage disorder, multiple sulfatase deficiency (MSD), it has been suggested that normal autophagic, endocytic, and lysosomal vesicle trafficking is essential for preventing neurodegeneration [56]. One of the earliest pathological signs observed in patients with AD is the accumulation of numerous enlarged autophagic and endosomal vesicles, due to defective autophagy-lysosomal degradation in neurons [33, 57, 58]. The defect may result from impaired vesicle fusion among autophagosomes, endosomes and lysosomes [34, 57, 59, 60] or failure of lysosomal acidification [61]. Aβ42 has been shown to induce autophagy and lysosomal degradation dysfunctions which may lead to indigestible Aβ storage inside the vesicles [62, 63].

The accumulated Aβ in the astrocytes was partly modified to N-terminally truncated Aβ. The absence of the full Aβ N-terminus may thereby, to some extent, underestimate the intracellular Aβ concentration when analyzing cell lysate with the N-terminus dependent Aβ1-x and Aβ protofibril ELISA. N-terminally truncated Aβ, often bearing amino-terminal Glu3 which eventually modifies to pyroglutamate (AβN3pE-x), is found both in extracellular, intracellular and vascular deposits in AD and Down's syndrome brain tissue [64]. Astrocytes have been implied to take up N-terminally truncated Aβ from fleecy amyloid in AD brains and diffuse plaques from non-demented individuals [65, 66]. As we exposed astrocytes with full length Aβ42 in the protofibrillar form, we propose that the truncation of Aβ in fact might occur by the endosomal/lysosomal pathway in the astrocytes. Since the N-terminals are sticking out from the Aβ protofibrils, they are easily accessible, compared to the C-terminals that are hidden in the core of the aggregate. We suggest that since the astrocytes degradation system is ineffective, degradation is not completed and partly degraded (N-terminally truncated) Aβ is left. N-terminally truncated Aβ has been found to be more resistant to degradation, more prone to aggregate and more toxic than full - length Aβ [67]. Our hypothesis is that astrocytes try to be “helpful”, but are overwhelmed by the difficulties they face. Hence, they cannot fulfill their task to degrade the Aβ protofibrils, and instead of being “helpful” they promote spreading of the Aβ pathology, by secreting Aβ aggregates that had been only partly degraded. In the AD brain, reactive astrocytes are attracted to the Aβ plaques and are highly exposed to various forms of Aβ aggregates. Engulfment of Aβ by astrocytes may initially be a protective clearance mechanism, but based on our data, overburden of the astrocytes is clearly detrimental.

Astrocytes are highly responsible for maintaining brain homeostasis and although our results show that the high Aβ load does not induce apoptosis in astrocytes, their normal functions are probably severely affected. Misconduct in the performance of astrocytes normal responsibilities would affect processes such as metabolic support of neurons, modification of synapse signaling, recycling of neurotransmittors, regulation of blood flow and function of the blood brain barrier [2, 3].

The way in which Aβ pathology spreads in the AD brain has been debated for many years. Experimental evidence suggests that amyloid proteins, such as Aβ, indeed can seed and transmit pathology in the brain. For example, it has been shown that injection of cortical extracts from post-mortem AD brains into the brains of transgenic APP mice, aggravates plaque pathology within five months [68] and longer incubation also induces tau pathology [69]. The cellular mechanism behind the spreading of AD pathology is still unclear, but both cell-to-cell transmission [70] and secretion into the extracellular space [71] have been suggested as possible pathways. Ineffective degradation of Aβ may lead to spreading of AD pathology, due to secretion of Aβ containing microvesicles [35, 72]. Interestingly, Aβ peptides have been found to be released from AβPP transfected neuroblastoma cells via exosomes. Moreover, the exosome specific proteins Alix and Flotillin-1, have been found around plaques in human AD brains and within senile plaques of Tg2756 mice, respectively [72, 73]. We have previously shown that astrocytes express high levels of proteins known to promote vesicle secretion [26, 30, 74, 75]. In contrast to neurons, which mainly secrete Aβ beginning at Asp1, the majority of Aβ secreted from glial cells has proven to be N-terminally truncated [76].

Conclusion

In conclusion, we demonstrate that astrocytes engulf large amounts of protofibrillar Aβ42 that are only partly digested and stored in the cells for very long times. The intracellular Aβ accumulation results in severe astrocytic endosome/lysosome defects and microvesicle-induced neurotoxicity. In familial AD, with mutations in the AβPP, Presenilin 1 or Presenilin 2 genes, increased Aβ production or increased Aβ42/Aβ40 ratio lead to AD. However, in sporadic AD it is likely that defective Aβ clearance is the culprit. Thus, accumulation of Aβ in astrocytes could play a vital role in the sporadic form of the disease and a better understanding of astrocytes role in AD initiation and progression is highly desirable.

Methods

Synthetic Aβ42 protofibrils

Fluorescent HiLyte™ Fluor 555-labeled Aβ42 (Aβ42-555) peptides (Anaspec Inc) were diluted in 10 x phosphate buffered saline (PBS) to a concentration of 36 μM followed by incubation for 4 h at 37 °C. Synthetic Aβ42 peptides (American Peptide Company Inc.) were prepared as previously described [13, 77–79]. Aβ42 dissolved in 10 mM NaOH was mixed with 10 x PBS to 443 μM (2 mg/ml) and incubated 30 min at 37 °C. Both Aβ42-555 protofibrils and unlabeled Aβ42 protofibrils were centrifuged for 5 min at 17 900 x g to remove any insoluble aggregates. Using the protofibril specific ELISA, mAb158 [41], we concluded that we had the best yield of Aβ42-555 protofibrils after 4 h incubation in 37 °C. Aβ42-555 protofibrils were readily detected by mAb158 ELISA and there was no significant difference between 555-labeled and unlabeled Aβ42 protofibrils (Additional file 13). To estimate the purity (>95 %) and size of the Aβ42 protofibrils, 50 μl of 250 μg/ml Aβ42 protofibrils were analyzed by size-exclusion chromatography (SEC) using a Superdex 75 column. The Aβ42 protofibrils (>95 % purity) eluted in the void volume and was estimated to be >75 kDa based on the cutoff size of the Superdex column (Fig. 9).
Fig. 9
Fig. 9

Aβ42 protofibril characterization. A chromatogram following Aβ42 protofibril analysis by SEC using a Superdex 75 column. The chromatograms show mV for the absorbance at 214 nm on the y-axis and the retention time in minutes on the x-axis

Animals

All experiments involving animals were performed at Uppsala University, Sweden. The experiments were approved by the Uppsala County Animal Ethics Board (ethical permit number: C75/13, valid 2013-06-28 to 2018-06-28), following the rules and regulations of the Swedish Animal Welfare Agency, in compliance with the European Communities Council Directive of 22 September 2010 (2010/63/EU). C57/BL6 mice were used for cell culture studies and tg-ArcSwe mice, harboring the human Arctic (E693G) and Swedish (KM670/671NL) AβPP mutations (Lord 2007) for in vivo experiments. The animals were housed at the National Veterinary Institute, Uppsala or the animal facility at Uppsala University Hospital, Uppsala in a 12-12 dark-light cycle. The mice were kept in an enriched environment and given water and food ad libitum.

Neural cell cultures

Cerebral cortices from C57/BL6 mice of embryonal day 14 (E14) were dissected in Hank’s buffered salt solution supplemented with 50 U/ml Penicillin, 50 mg/ml Streptomycin and 8 mM Hepes buffer (HBSS, all from Invitrogen). The cortices were dissociated in fresh HBSS, centrifuged at 150 x g and resuspended in cell culture medium.

Co-cultures of neurons and glia

According to Loov et al. [30], the cells were expanded in DMEM/F12-GlutaMAX supplemented with 1 x B27, 50 U/ml Penicillin, 50 mg/ml Streptomycin and 8 mM Hepes buffer, 10 ng/ml bFGF (all from Invitrogen) and 20 mg/ml EGF (VWR). Neurospheres were passaged every second or third day by dissociation in HBSS and resuspended in medium with bFGF and EGF. Prior to experiments, the cells were plated as a monolayer, at a concentration of 1.5 × 105 cells/ml, on cover slips (In Vitro Diagnostics) or cell culture dishes (Falcon), coated with Poly-L-Ornithine (Sigma-Aldrich) and Laminin (Invitrogen). After 24 h, the medium was replaced with mitogen-free medium to initiate neural stem cell differentiation to a mixed population of neurons, astrocytes and oligodendrocytes, but not microglia. This is a well characterized cell culture system, based on the lineage restricted differentiation of embryonic, cortical stem cells [38, 80, 81]. To drive the differentiation towards generation of exclusively astrocytes, 10 ng/ml cilliary neurotrophic factor (CNTF) was added to the mitogen-free medium throughout the differentiation process [37, 38]. During the seven days differentiation period, the cell culture medium was changed every second or third day. Only neurospheres from passage 2–4 were used for experiments.

Neuronal cultures

Following dissection and dissociation the cells were seeded on Poly-L-Ornithine and Laminin coated cover slips at a concentration of 8 × 104 cells/ml. The neurons were cultured in neurobasal medium supplemented with 1 x B27, 50 U/ml Penicillin, 50 mg/ml Streptomycin and 20 mM L-glutamine (Invitrogen) for 12 days (12 DIV) prior to experiment. The first day after seeding, the cell culture medium was fully replaced followed by changing half of the medium every second or third day.

Aβ stimulation

Cell cultures differentiated into neurons and glia or astrocytes and pure neuronal cultures were treated with 0.1 μM Aβ42 protofibrils (either 555-labeled or unlabeled) for 24 h. Controls received fresh cell culture medium without Aβ42 protofibrils. After Aβ treatment, the cells were washed in cell culture media x 3 and the cover slips were transferred to new culture dishes. The cells were fixed, lysed (24 h) or cultured for additional 6 (24 h + 6 days) or 12 days (24 h + 12 days) in Aβ free - cell culture medium prior to fixation or cell lysis.

Microvesicles

Co-cultures of neurons and glia were treated with 0.1 μM Aβ42 protofibrils for 24 h or left untreated. The cultures were thoroughly washed x 3 and were continuously cultured in medium only. From day 6 to day 12 following Aβ42 protofibril treatment, the medium was harvested and centrifuged for 5 min at 300 x g to remove any cell remnants. For microvesicle preparations (containing exosomes and larger vesicles), the supernatants were centrifuged for 10 min at 2000 x g to remove apoptotic bodies followed by ultracentrifugation for 1.5 h at 4 °C at 135 000 x g. The ultracentrifugation was performed in Ultra-Clear centrifuge tubes (Beckman Coulter) using a Beckman LE-80 ultracentrifuge. For the neurotoxicity assays, the pellets containing microvesicles were reconstituted in neurobasal medium supplemented with 1 x B27, Penicillin and Streptomycin and L-glutamine (Invitrogen) and added to cortical neurons. After 48 h, the neuronal cultures were fixed and the number of apoptotic cells quantified. Parallel control cultures were exposed to 0.1 μM Aβ42 protofibrils or left untreated for 48 h prior to fixation. For analysis of the Aβ content, the isolated microvesicles were lysed in ice cold lysis buffer (20 mM Tris pH 7.5, 0.5 % Triton X-100, 0.5 % deoxycholic acid, 150 mM NaCl, 10 mM EDTA, 30 mM NaPyroP and protease inhibitor (Roche)) and stored in −70 °C until time of analysis by ELISA.

Immunostaining of cell cultures

Cover slips were fixed for 15 min in RT with 4 % paraformaldehyde and permeabilized and blocked with 0.1 % Triton X-100 (both from Sigma-Aldrich) and 5 % normal goat serum (NGS, Bionordica) in PBS for 30 min in RT. Primary antibodies were incubated in 0.1 % Triton X-100 with 0.5 % NGS for 1–4 h in RT or O/N in 4 °C. Thereafter, cover slips were washed thoroughly in PBS x 3 between each step. Incubation with secondary antibodies was performed in 0.1 % Triton X-100 and 0.5 % NGS for 45 min in 37 °C or 1 h in RT. The following primary antibodies were used in the study: rabbit anti-Glial Fibrillary Acidic Protein (GFAP, 1:400, DakoCytomation), mouse anti-GFAP (1:400, Sigma-Aldrich), mouse anti-2',3'-Cyclic-nucleotide 3'-phosphodiesterase (CNPase, 1:500, Sigma-Aldrich), mouse anti-βIII tubulin (1:200, Covance), rabbit anti-Lysosome-associated membrane protein-1 (LAMP-1, 1:200, Abcam), rabbit anti-Rab5 (1:1000, Abcam), mouse anti-Rab7 (1:1000, Abcam), polyclonal rabbit anti-Aβ42 (1:200, Invitrogen), monoclonal mouse anti-Aβ antibody, 6E10 (10 μg/ml, epitope: 3-8, Signet), the monoclonal mouse anti-Aβ antibody, mAb1C3 (10 μg/ml, epitope: 3-8) [41] and monoclonal mouse anti-Aβ protofibril selective antibody, mAb158 (10 μg/ml) [41]. Secondary antibodies used were: AlexaFluor 488, 555 and 647, all against mouse or rabbit (1:200, Molecular probes). To study acidic lysosomes, 0.5 μM LysoTracker red DND-99 (ThermoFisher) was added to the cell culture medium 2 h prior to fixation. Neuronal apoptosis was measured using terminal (TdT)-mediated dUTP-biotin reaction mixture (TUNEL, Roche Biochemicals) according to the manufacturer’s instructions. The cover slips were mounted on microscope glass slides using vectashield hard set mounting medium with DAPI (DAKO). A Zeiss Observer Z1 Microscope and Carl Zeiss LSM700 confocal microscope (Zeiss) were used for analysis. Images and confocal z-stacks were visualized with Zen 2012 software.

Time-lapse experiments

Time-lapse experiments were performed at 37 °C in humidified 5 % CO2 in air, using a Nikon Biostation IM Live Cell Recorder (Nikon). The cells were cultured at a concentration of 1.5 × 105 cells/ml, in time-lapse culture dishes (VWR) and pictures were taken every 10th minute for up to 5 days.

Transmission electron microscopy

Cells

Cells were briefly washed in PBS prior to fixation in 2.5 % glutaraldehyde (1 h or O/N in 4 °C). The dishes containing the cells were rinsed in 0.15 M Na-caccodylate and incubated for 1 h in 1 % osmium tetroxide in Na-caccodylate at RT followed by Na-caccodylate rinse. Dehydration was performed with 70 % ethanol for 30 min, 95 % ethanol for 30 min and 99.7 % ethanol for 1 h. A thin layer of newly made plastic (Agar 100 resin kit, Agar Scientific Ltd) was added for 1 h to permit evaporation of the alcohol. The plastic was poured off and a second plastic layer was added and left O/N in a desiccator. Next, plastic was heated up in an oven to enable its removal and a thicker, newly made plastic layer was added. The dishes were incubated in desiccator for 1–4 h before polymerization in oven (60 °C) for 48 h. Cells were sectioned using Leica ultracut UTC ultrotome (Rowaco AB) and studied in a Tecnai G2 transmission electron microscope (FEI Company). ORIUS SC200 CCD was used as camera and Gatan Digital Micrograph as software (both Gatan Inc.).

Microvesicles

Microvesicles were isolated by ultracentrifugation as described above and reconstituted in PBS. Samples were added onto a formvar-coated 200-mesh grid (Oxford Instruments) and incubated for 45 min in RT. The grid was dried and 1 % uranyl acetate was added for 10 s. Before analysis in a Tecnai G2 transmission electron microscope (FEI Company), the grid was dried for at least 15 min. ORIUS SC200 CCD was used as camera and Gatan Digital Micrograph as software (both Gatan Inc.).

Cell lysates

For Aβ quantification studies, co-cultures of neurons and glia were seeded out in a concentration of 2.4 × 105 cells/ml in 60 mm x 15 mm cell culture dishes (Corning). Following removal of the cell culture medium, 100 μl ice cold lysis buffer (20 mM Tris pH 7.5, 0.5 % Triton X-100, 0.5 % deoxycholic acid, 150 mM NaCl, 10 mM EDTA, 30 mM NaPyroPand protease inhibitor, Roche) was added to the dish. The lysed cells were collected using a cell lifter (Costar), transferred to Eppendorf tubes, incubated on ice for 30 min and centrifuged (30 min, 4 °C, 12 000 x g). The supernatant was collected and the remaining pellet was dissolved in 50 % formic acid and sonicated in 4 × 4 s pulses for 30 effective seconds at 50 % amplitude. Both the supernatants and pellets were stored in −70 °C until time of analysis by ELISA.

Aβ1-x and Aβx-42 ELISAs

For Aβ1-x ELISA [82] ninety-six well EIA/RIA plates (Corning Inc.) were coated O/N at 4 °C with the N-terminus (epitope 1-5) antibody mAb82E1 (100 ng/well, IBL-Hamburg) in PBS. Plates were blocked with 1 % bovine serum albumin (BSA) in PBS for 2 h in RT. Standard series of synthetic Aβ42 monomers (American Peptide) and samples (all except pellets of the lysates) were denatured by boiling for 5 min in 0.5 % sodium dodecyl sulfate (SDS) to avoid impaired detection caused by aggregated Aβ [83]. Before addition to plates, all SDS treated samples were diluted x 10 to decrease the SDS concentration and incubation followed for 2 h. Biotinylated mAb4G8 (0.3 μg/ml, Covance), specific for the mid region of Aβ, was used as secondary antibody and incubated for 1 h followed by incubation with streptavidin coupled HRP (1:2000, Mabtech AB) for 1 h. K-blue enhanced (Neogen Corporation) was used as HRP substrate and the reaction was stopped with 1 M H2SO4. Plates were measured by Tecan Infinite M200 PRO spectrophotometer (Tecan Group Ltd.) at 450 nm and analyzed with Magellan v7.0 software (Tecan Group Ltd.). Washing was performed by adding 250 μl washing buffer (phosphate buffered NaCl with 0.1 % Tween 20 and 0.15 % Kathon) x 3 repetitions between each step of the ELISA. All dilutions occurred in ELISA incubation buffer (0.05 % Tween, 0.1 % BSA and 0.15 % Kathon in PBS at pH 7.4). For the Aβx-42 ELISA, polyclonal Aβ42 antibody (100 ng/well, Agrisera) and biotinylated mAb4G8 (0.5 μg/ml) was used as primary and secondary antibody, respectively. Aβx-42 ELISA [13] was performed according to the same protocol as the Aβ1-x ELISA, except for prolonged incubation times for blocking, sample (both O/N, 4 °C) and secondary antibody (2 h, RT) and increased SA-HRP dilution (1:5000). The pellet samples were neutralized with 1 M Trizma base + 0.5 M Na2HPO4 prior to the ELISA analysis.

Aβ protofibril ELISA

Aβ protofibril ELISA using mAb158, was performed according to the protocol described by Englund et al. [41]. In short, ninety-six well EIA/RIA plates (Corning Inc.) were coated with 200 ng/well of mAb158 in 100 μl PBS at 4 °C O/N. Plates were blocked with 1 % BSA in PBS with 0.15 % Kathon. Standard series of synthetic Aβ42 protofibrils and samples were added to the plates for 2 h incubation in RT. All dilutions occurred in ELISA incubation buffer. After washing the plate, 0.5 μg/ml of biotinylated mAb158 was added and incubated for 1 h in RT. Subsequent steps and washing steps were performed as previously described in the Aβ 1-x ELISA method.

Immunostaining of mouse brain tissue

Twelve-fourteen-month-old tg-ArcSwe mice were perfused with isotonic saline solution followed by 4 % phosphate-buffered formaldehyde (Histolab AB). The brains were frozen and cryo-sectioned sagittally to a thickness of 14 μm and then permeabilized and blocked in 0.3 % Triton X-100 in PBS containing 5 % NGS for 1 h in RT. The sections were incubated at 4 °C O/N with primary antibody diluted in 0.3 % Triton/PBS with 0.5 % NGS and thoroughly washed in 0.3 % Triton/PBS. Thereafter, sections were incubated for 1 h in RT with secondary antibody diluted in 0.3 % Triton/PBS with 0.5 % NGS before repeating the washing step. The sections were mounted on microscope glass slides with Vectashield containing DAPI (Vector). Primary antibodies used were: rabbit anti-GFAP (1:400, DakoCytomation), mouse anti-GFAP (1:500, Sigma), rat anti-LAMP-2 (1:400, Abcam) and mAb158 (5 μg/ml). Secondary antibodies used were AlexaFluor 488 against mouse, rabbit and rat or AlexaFluor 555 against mouse and rabbit (1:500, Molecular probes).

Western blot analysis

Microvesicle lysates were prepared as described above. 26 μl of each sample was loaded to a 4–12 % Bis-Tris Gel (NuPAGE, Life Technologies). Novex® Sharp Standard (Life technologies) was used as a standard. The gel was run for 1 h at 175 V in MES buffer (NuPage, Life Technologies) followed by transfer for 1 h at 20 V onto a PVDF membrane (Invitrogen). The membrane was blocked with 5 % BSA in TBS with 0.2 % Tween (TBS-T) for 1 h (RT), followed by washes in TBS-T and incubation with Flotillin-1 (mouse monoclonal, 1:500, BD Biosciences) antibody in 0.5 % BSA in TBS-T over night (4 °C). After extensive washes in TBS-T the membrane was incubated with a peroxidase-conjugated goat anti-mouse IgG (1:20 000, Pierce) antibody in 0.5 % BSA in TBS-T for 1 h (RT) and then finally washed again in TBS-T. The enhanced chemiluminescence (ECL) system (GE Healthcare) was used for development.

Aβ inclusions, area, intensity measures and cell counting

Thirty images (10 images/cover slip from three independent cultures) were captured with an x40 objective on a Zeiss Observer Z1, using exactly the same settings. For the co-localization studies the images were manually analyzed. The cells were divided into four categories; cells with no detectable levels of Aβ42-555 protofibrils (−), cells with only small amounts of Aβ42-555 protofibrils (+), cells containing medium amounts (a couple of small Aβ42-555 protofibril inclusions or larger Aβ42 protofibril inclusions with low intensity of the 555-staining) (++) and cells with one or more large Aβ42-555 protofibril inclusions (+++). For Aβ intensity and area measurements, the images were analyzed with the Zen 2012 software (Zeiss). All area and intensity measurements of Aβ were set manually in the software and the number of viable cells was determined by manually counting cell nuclei in each field. Due to low cell numbers, the x20 objective was used when counting the number of viable neurons and oligodendrocytes. All images were analyzed in a blinded fashion.

Statistics

All experiments were performed in triplicates with independent cell cultures derived from embryos of different pregnant mice. The results are presented in scatter plots or box plots with mean +/− standard deviation. Since the data was found not to meet the assumption of normal distribution, using the Shapiro-Wilk’s W-test, unpaired t-test and Kruskal-Wallis ANOVA, followed by Mann–Whitney U-test for pair-wise comparisons was used. Level of significance were set to *P < 0.05, ** < 0.01 and *** < 0.001.

Abbreviations

12 DIV: 

12 days in vitro

AD: 

Alzheimer’s disease

Aβ: 

amyloid beta

BSA: 

bovine serum albumin

CNPase: 

2',3'-Cyclic-nucleotide 3'-phosphodiesterase

CNTF: 

cilliary neurotrophic factor

CSF: 

cerebrospinal fluid

E14: 

embryonal day 14

ECL: 

enhanced chemiluminescence

GFAP: 

glial fibrillary acidic protein

HBSS: 

Hank’s buffered salt solution

LAMP-1: 

lysosome-associated membrane protein-1

LAMP-2: 

lysosome-associated membrane protein-2

MSD: 

multiple sulfatase deficiency

NGS: 

normal goat serum

PBS: 

phosphate buffered saline

SDS: 

sodium dodecyl sulfate

SEC: 

size-exclusion chromatography

TFEB: 

transcription factor EB

TUNEL: 

terminal (TdT)-mediated dUTP-biotin reaction mixture

Declarations

Acknowledgements

This study was supported by grants from the Swedish Research Council (#2012-2172), the Alzheimer Foundation, Åhlén Foundation, Stohnes Foundation, Magnus Bergvalls Foundation and the Uppsala Berzelii Centre.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Public Health & Caring Sciences/Molecular Geriatrics, Rudbeck Laboratory, Uppsala University, SE-751 85 Uppsala, Sweden
(2)
BioArctic Neuroscience AB, Warfvinges väg 35, SE-112 51 Stockholm, Sweden

References

  1. Avila-Munoz E, Arias C. When astrocytes become harmful: Functional and inflammatory responses that contribute to Alzheimer’s disease. Ageing Res Rev. 2014;18C:29–40.View ArticleGoogle Scholar
  2. Sofroniew MV, Vinters HV. Astrocytes: biology and pathology. Acta Neuropathol. 2010;119:7–35.View ArticlePubMedPubMed CentralGoogle Scholar
  3. Eroglu C, Barres BA. Regulation of synaptic connectivity by glia. Nature. 2010;468:223–31.View ArticlePubMedPubMed CentralGoogle Scholar
  4. Pekny M, Wilhelmsson U, Pekna M. The dual role of astrocyte activation and reactive gliosis. Neurosci Lett. 2014;565:30–8.View ArticlePubMedGoogle Scholar
  5. Hardy JA, Higgins GA. Alzheimer’s disease: the amyloid cascade hypothesis. Science. 1992;256:184–5.View ArticlePubMedGoogle Scholar
  6. Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, Beach T, Kurth JH, Rydel RE, Rogers J. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer’s disease. Am J Pathol. 1999;155:853–62.View ArticlePubMedPubMed CentralGoogle Scholar
  7. McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, Bush AI, Masters CL. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer’s disease. Ann Neurol. 1999;46:860–6.View ArticlePubMedGoogle Scholar
  8. Hartley DM, Walsh DM, Ye CP, Diehl T, Vasquez S, Vassilev PM, Teplow DB, Selkoe DJ. Protofibrillar intermediates of amyloid beta-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J Neurosci. 1999;19:8876–84.PubMedGoogle Scholar
  9. Klyubin I, Walsh DM, Cullen WK, Fadeeva JV, Anwyl R, Selkoe DJ, Rowan MJ. Soluble Arctic amyloid beta protein inhibits hippocampal long-term potentiation in vivo. Eur J Neurosci. 2004;19:2839–46.View ArticlePubMedGoogle Scholar
  10. Klyubin I, Cullen WK, Hu NW, Rowan MJ. Alzheimer’s disease Abeta assemblies mediating rapid disruption of synaptic plasticity and memory. Mol Brain. 2012;5:25.View ArticlePubMedPubMed CentralGoogle Scholar
  11. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002;416:535–9.View ArticlePubMedGoogle Scholar
  12. Lacor PN, Buniel MC, Furlow PW, Clemente AS, Velasco PT, Wood M, Viola KL, Klein WL. Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer’s disease. J Neurosci. 2007;27:796–807.View ArticlePubMedGoogle Scholar
  13. Sehlin D, Englund H, Simu B, Karlsson M, Ingelsson M, Nikolajeff F, Lannfelt L, Pettersson FE. Large aggregates are the major soluble Abeta species in AD brain fractionated with density gradient ultracentrifugation. PLoS One. 2012;7:e32014.View ArticlePubMedPubMed CentralGoogle Scholar
  14. Tucker S, Moller C, Tegerstedt K, Lord A, Laudon H, Sjodahl J, Soderberg L, Spens E, Sahlin C, Waara ER, et al. The murine version of BAN2401 (mAb158) selectively reduces amyloid-beta protofibrils in brain and cerebrospinal fluid of tg-ArcSwe mice. J Alzheimers Dis. 2015;43:575–88.PubMedGoogle Scholar
  15. Savage MJ, Kalinina J, Wolfe A, Tugusheva K, Korn R, Cash-Mason T, Maxwell JW, Hatcher NG, Haugabook SJ, Wu G, et al. A sensitive abeta oligomer assay discriminates Alzheimer’s and aged control cerebrospinal fluid. J Neurosci. 2014;34:2884–97.View ArticlePubMedGoogle Scholar
  16. Holtta M, Hansson O, Andreasson U, Hertze J, Minthon L, Nagga K, Andreasen N, Zetterberg H, Blennow K. Evaluating amyloid-beta oligomers in cerebrospinal fluid as a biomarker for Alzheimer’s disease. PLoS One. 2013;8:e66381.View ArticlePubMedPubMed CentralGoogle Scholar
  17. Herskovits AZ, Locascio JJ, Peskind ER, Li G, Hyman BT. A Luminex assay detects amyloid beta oligomers in Alzheimer’s disease cerebrospinal fluid. PLoS One. 2013;8:e67898.View ArticlePubMedPubMed CentralGoogle Scholar
  18. Fukumoto H, Tokuda T, Kasai T, Ishigami N, Hidaka H, Kondo M, Allsop D, Nakagawa M. High-molecular-weight beta-amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients. FASEB J. 2010;24:2716–26.View ArticlePubMedGoogle Scholar
  19. Orre M, Kamphuis W, Osborn LM, Melief J, Kooijman L, Huitinga I, Klooster J, Bossers K, Hol EM. Acute isolation and transcriptome characterization of cortical astrocytes and microglia from young and aged mice. Neurobiol Aging. 2014;35:1–14.View ArticlePubMedGoogle Scholar
  20. Sastre M, Klockgether T, Heneka MT. Contribution of inflammatory processes to Alzheimer’s disease: molecular mechanisms. Int J Dev Neurosci. 2006;24:167–76.View ArticlePubMedGoogle Scholar
  21. Jones RS, Minogue AM, Connor TJ, Lynch MA. Amyloid-beta-induced astrocytic phagocytosis is mediated by CD36, CD47 and RAGE. J Neuroimmune Pharmacol. 2013;8:301–11.View ArticlePubMedGoogle Scholar
  22. Chung WS, Clarke LE, Wang GX, Stafford BK, Sher A, Chakraborty C, Joung J, Foo LC, Thompson A, Chen C, et al. Astrocytes mediate synapse elimination through MEGF10 and MERTK pathways. Nature. 2013;504:394–400.View ArticlePubMedPubMed CentralGoogle Scholar
  23. Chang GH, Barbaro NM, Pieper RO. Phosphatidylserine-dependent phagocytosis of apoptotic glioma cells by normal human microglia, astrocytes, and glioma cells. Neuro Oncol. 2000;2:174–83.PubMedPubMed CentralGoogle Scholar
  24. Magnus T, Chan A, Linker RA, Toyka KV, Gold R. Astrocytes are less efficient in the removal of apoptotic lymphocytes than microglia cells: implications for the role of glial cells in the inflamed central nervous system. J Neuropathol Exp Neurol. 2002;61:760–6.View ArticlePubMedGoogle Scholar
  25. Sokolowski JD, Nobles SL, Heffron DS, Park D, Ravichandran KS, Mandell JW. Brain-specific angiogenesis inhibitor-1 expression in astrocytes and neurons: implications for its dual function as an apoptotic engulfment receptor. Brain Behav Immun. 2011;25:915–21.View ArticlePubMedPubMed CentralGoogle Scholar
  26. Loov C, Hillered L, Ebendal T, Erlandsson A. Engulfing astrocytes protect neurons from contact-induced apoptosis following injury. PLoS One. 2012;7:e33090.View ArticlePubMedPubMed CentralGoogle Scholar
  27. Fellner L, Irschick R, Schanda K, Reindl M, Klimaschewski L, Poewe W, Wenning GK, Stefanova N. Toll-like receptor 4 is required for alpha-synuclein dependent activation of microglia and astroglia. Glia. 2013;61:349–60.View ArticlePubMedPubMed CentralGoogle Scholar
  28. Nielsen HM, Mulder SD, Belien JA, Musters RJ, Eikelenboom P, Veerhuis R. Astrocytic A beta 1-42 uptake is determined by A beta-aggregation state and the presence of amyloid-associated proteins. Glia. 2010;58:1235–46.PubMedGoogle Scholar
  29. Nagele RG, D’Andrea MR, Lee H, Venkataraman V, Wang HY. Astrocytes accumulate A beta 42 and give rise to astrocytic amyloid plaques in Alzheimer disease brains. Brain Res. 2003;971:197–209.View ArticlePubMedGoogle Scholar
  30. Loov C, Mitchell CH, Simonsson M, Erlandsson A. Slow degradation in phagocytic astrocytes can be enhanced by lysosomal acidification. Glia. 2015;63:1997-2009.Google Scholar
  31. Liebl D, Griffiths G. Transient assembly of F-actin by phagosomes delays phagosome fusion with lysosomes in cargo-overloaded macrophages. J Cell Sci. 2009;122:2935–45.View ArticlePubMedGoogle Scholar
  32. Appelqvist H, Waster P, Kagedal K, Ollinger K. The lysosome: from waste bag to potential therapeutic target. J Mol Cell Biol. 2013;5:214–26.View ArticlePubMedGoogle Scholar
  33. Nixon RA, Yang DS, Lee JH. Neurodegenerative lysosomal disorders: a continuum from development to late age. Autophagy. 2008;4:590–9.View ArticlePubMedGoogle Scholar
  34. Nixon RA. Autophagy, amyloidogenesis and Alzheimer disease. J Cell Sci. 2007;120:4081–91.View ArticlePubMedGoogle Scholar
  35. Dinkins MB, Dasgupta S, Wang G, Zhu G, Bieberich E. Exosome reduction in vivo is associated with lower amyloid plaque load in the 5XFAD mouse model of Alzheimer’s disease. Neurobiol Aging. 2014;35:1792–800.View ArticlePubMedPubMed CentralGoogle Scholar
  36. Middeldorp J, Hol EM. GFAP in health and disease. Prog Neurobiol. 2011;93:421–43.View ArticlePubMedGoogle Scholar
  37. Bonni A, Sun Y, Nadal-Vicens M, Bhatt A, Frank DA, Rozovsky I, Stahl N, Yancopoulos GD, Greenberg ME. Regulation of gliogenesis in the central nervous system by the JAK-STAT signaling pathway. Science. 1997;278:477–83.View ArticlePubMedGoogle Scholar
  38. Johe KK, Hazel TG, Muller T, Dugich-Djordjevic MM, McKay RD. Single factors direct the differentiation of stem cells from the fetal and adult central nervous system. Genes Dev. 1996;10:3129–40.View ArticlePubMedGoogle Scholar
  39. Philipson O, Hammarstrom P, Nilsson KP, Portelius E, Olofsson T, Ingelsson M, Hyman BT, Blennow K, Lannfelt L, Kalimo H, Nilsson LN. A highly insoluble state of Abeta similar to that of Alzheimer’s disease brain is found in Arctic APP transgenic mice. Neurobiol Aging. 2009;30:1393–405.View ArticlePubMedGoogle Scholar
  40. Lord A, Kalimo H, Eckman C, Zhang XQ, Lannfelt L, Nilsson LN. The Arctic Alzheimer mutation facilitates early intraneuronal Abeta aggregation and senile plaque formation in transgenic mice. Neurobiol Aging. 2006;27:67–77.View ArticlePubMedGoogle Scholar
  41. Englund H, Sehlin D, Johansson AS, Nilsson LN, Gellerfors P, Paulie S, Lannfelt L, Pettersson FE. Sensitive ELISA detection of amyloid-beta protofibrils in biological samples. J Neurochem. 2007;103:334–45.PubMedGoogle Scholar
  42. Naslund J, Haroutunian V, Mohs R, Davis KL, Davies P, Greengard P, Buxbaum JD. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA. 2000;283:1571–7.View ArticlePubMedGoogle Scholar
  43. Whalen BM, Selkoe DJ, Hartley DM. Small non-fibrillar assemblies of amyloid beta-protein bearing the Arctic mutation induce rapid neuritic degeneration. Neurobiol Dis. 2005;20:254–66.View ArticlePubMedGoogle Scholar
  44. Knobloch M, Farinelli M, Konietzko U, Nitsch RM, Mansuy IM. Abeta oligomer-mediated long-term potentiation impairment involves protein phosphatase 1-dependent mechanisms. J Neurosci. 2007;27:7648–53.View ArticlePubMedGoogle Scholar
  45. Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, Sabatini BL. Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci. 2007;27:2866–75.View ArticlePubMedGoogle Scholar
  46. Li S, Jin M, Koeglsperger T, Shepardson NE, Shankar GM, Selkoe DJ. Soluble Abeta oligomers inhibit long-term potentiation through a mechanism involving excessive activation of extrasynaptic NR2B-containing NMDA receptors. J Neurosci. 2011;31:6627–38.View ArticlePubMedPubMed CentralGoogle Scholar
  47. Basak JM, Verghese PB, Yoon H, Kim J, Holtzman DM. Low-density lipoprotein receptor represents an apolipoprotein E-independent pathway of Abeta uptake and degradation by astrocytes. J Biol Chem. 2012;287:13959–71.View ArticlePubMedPubMed CentralGoogle Scholar
  48. Koistinaho M, Lin S, Wu X, Esterman M, Koger D, Hanson J, Higgs R, Liu F, Malkani S, Bales KR, Paul SM. Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-beta peptides. Nat Med. 2004;10:719–26.View ArticlePubMedGoogle Scholar
  49. Xiao Q, Yan P, Ma X, Liu H, Perez R, Zhu A, Gonzales E, Burchett JM, Schuler DR, Cirrito JR, et al. Enhancing astrocytic lysosome biogenesis facilitates Abeta clearance and attenuates amyloid plaque pathogenesis. J Neurosci. 2014;34:9607–20.View ArticlePubMedPubMed CentralGoogle Scholar
  50. Kanekiyo T, Zhang J, Liu Q, Liu CC, Zhang L, Bu G. Heparan sulphate proteoglycan and the low-density lipoprotein receptor-related protein 1 constitute major pathways for neuronal amyloid-beta uptake. J Neurosci. 2011;31:1644–51.View ArticlePubMedPubMed CentralGoogle Scholar
  51. Guenette SY. Astrocytes: a cellular player in Abeta clearance and degradation. Trends Mol Med. 2003;9:279–80.View ArticlePubMedGoogle Scholar
  52. Nicoll JA, Weller RO. A new role for astrocytes: beta-amyloid homeostasis and degradation. Trends Mol Med. 2003;9:281–2.View ArticlePubMedGoogle Scholar
  53. Shafer LE. Charging Ahead: An Introduction to Electromagnetism. In: Book Charging Ahead: An Introduction to Electromagnetism. City: National Science Teachers Association; 2001. p. 81.Google Scholar
  54. Barrachina M, Maes T, Buesa C, Ferrer I. Lysosome-associated membrane protein 1 (LAMP-1) in Alzheimer’s disease. Neuropathol Appl Neurobiol. 2006;32:505–16.View ArticlePubMedGoogle Scholar
  55. Hashimoto T, Ogino K, Shin RW, Kitamoto T, Kikuchi T, Shimizu N. Age-dependent increase in lysosome-associated membrane protein 1 and early-onset behavioral deficits in APPSL transgenic mouse model of Alzheimer’s disease. Neurosci Lett. 2010;469:273–7.View ArticlePubMedGoogle Scholar
  56. Di Malta C, Fryer JD, Settembre C, Ballabio A. Astrocyte dysfunction triggers neurodegeneration in a lysosomal storage disorder. Proc Natl Acad Sci U S A. 2012;109:E2334–2342.View ArticlePubMedPubMed CentralGoogle Scholar
  57. Nixon RA, Wegiel J, Kumar A, Yu WH, Peterhoff C, Cataldo A, Cuervo AM. Extensive involvement of autophagy in Alzheimer disease: an immuno-electron microscopy study. J Neuropathol Exp Neurol. 2005;64:113–22.View ArticlePubMedGoogle Scholar
  58. Shacka JJ, Roth KA, Zhang J. The autophagy-lysosomal degradation pathway: role in neurodegenerative disease and therapy. Front Biosci. 2008;13:718–36.View ArticlePubMedGoogle Scholar
  59. Boland B, Kumar A, Lee S, Platt FM, Wegiel J, Yu WH, Nixon RA. Autophagy induction and autophagosome clearance in neurons: relationship to autophagic pathology in Alzheimer’s disease. J Neurosci. 2008;28:6926–37.View ArticlePubMedPubMed CentralGoogle Scholar
  60. Yu WH, Cuervo AM, Kumar A, Peterhoff CM, Schmidt SD, Lee JH, Mohan PS, Mercken M, Farmery MR, Tjernberg LO, et al. Macroautophagy--a novel Beta-amyloid peptide-generating pathway activated in Alzheimer’s disease. J Cell Biol. 2005;171:87–98.View ArticlePubMedPubMed CentralGoogle Scholar
  61. Lee JH, Yu WH, Kumar A, Lee S, Mohan PS, Peterhoff CM, Wolfe DM, Martinez-Vicente M, Massey AC, Sovak G, et al. Lysosomal proteolysis and autophagy require presenilin 1 and are disrupted by Alzheimer-related PS1 mutations. Cell. 2010;141:1146–58.View ArticlePubMedPubMed CentralGoogle Scholar
  62. Ling D, Salvaterra PM. Brain aging and Abeta(1)(-)(4)(2) neurotoxicity converge via deterioration in autophagy-lysosomal system: a conditional Drosophila model linking Alzheimer’s neurodegeneration with aging. Acta Neuropathol. 2011;121:183–91.View ArticlePubMedGoogle Scholar
  63. Ling D, Song HJ, Garza D, Neufeld TP, Salvaterra PM. Abeta42-induced neurodegeneration via an age-dependent autophagic-lysosomal injury in Drosophila. PLoS One. 2009;4:e4201.View ArticlePubMedPubMed CentralGoogle Scholar
  64. Perez-Garmendia R, Hernandez-Zimbron LF, Morales MA, Luna-Munoz J, Mena R, Nava-Catorce M, Acero G, Vasilevko V, Viramontes-Pintos A, Cribbs DH, Gevorkian G. Identification of N-terminally truncated pyroglutamate amyloid-beta in cholesterol-enriched diet-fed rabbit and AD brain. J Alzheimers Dis. 2014;39:441–55.PubMedGoogle Scholar
  65. Thal DR, Schultz C, Dehghani F, Yamaguchi H, Braak H, Braak E. Amyloid beta-protein (Abeta)-containing astrocytes are located preferentially near N-terminal-truncated Abeta deposits in the human entorhinal cortex. Acta Neuropathol. 2000;100:608–17.View ArticlePubMedGoogle Scholar
  66. Yamaguchi H, Sugihara S, Ogawa A, Saido TC, Ihara Y. Diffuse plaques associated with astroglial amyloid beta protein, possibly showing a disappearing stage of senile plaques. Acta Neuropathol. 1998;95:217–22.View ArticlePubMedGoogle Scholar
  67. De Kimpe L, van Haastert ES, Kaminari A, Zwart R, Rutjes H, Hoozemans JJ, Scheper W. Intracellular accumulation of aggregated pyroglutamate amyloid beta: convergence of aging and Abeta pathology at the lysosome. Age. 2013;35:673–87.View ArticlePubMedPubMed CentralGoogle Scholar
  68. Kane MD, Lipinski WJ, Callahan MJ, Bian F, Durham RA, Schwarz RD, Roher AE, Walker LC. Evidence for seeding of beta -amyloid by intracerebral infusion of Alzheimer brain extracts in beta -amyloid precursor protein-transgenic mice. J Neurosci. 2000;20:3606–11.PubMedGoogle Scholar
  69. Walker LC, Callahan MJ, Bian F, Durham RA, Roher AE, Lipinski WJ. Exogenous induction of cerebral beta-amyloidosis in betaAPP-transgenic mice. Peptides. 2002;23:1241–7.View ArticlePubMedGoogle Scholar
  70. Nath S, Agholme L, Kurudenkandy FR, Granseth B, Marcusson J, Hallbeck M. Spreading of neurodegenerative pathology via neuron-to-neuron transmission of beta-amyloid. J Neurosci. 2012;32:8767–77.View ArticlePubMedGoogle Scholar
  71. Zhao Y, Cui JG, Lukiw WJ. Natural secretory products of human neural and microvessel endothelial cells: Implications in pathogenic “spreading” and Alzheimer’s disease. Mol Neurobiol. 2006;34:181–92.View ArticlePubMedGoogle Scholar
  72. Rajendran L, Honsho M, Zahn TR, Keller P, Geiger KD, Verkade P, Simons K. Alzheimer’s disease beta-amyloid peptides are released in association with exosomes. Proc Natl Acad Sci U S A. 2006;103:11172–7.View ArticlePubMedPubMed CentralGoogle Scholar
  73. Kokubo H, Saido TC, Iwata N, Helms JB, Shinohara R, Yamaguchi H. Part of membrane-bound Abeta exists in rafts within senile plaques in Tg2576 mouse brain. Neurobiol Aging. 2005;26:409–18.View ArticlePubMedGoogle Scholar
  74. Ostrowski M, Carmo NB, Krumeich S, Fanget I, Raposo G, Savina A, Moita CF, Schauer K, Hume AN, Freitas RP, et al. Rab27a and Rab27b control different steps of the exosome secretion pathway. Nat Cell Biol. 2010;12:19–30. sup pp 11-13.View ArticlePubMedGoogle Scholar
  75. Jancic C, Savina A, Wasmeier C, Tolmachova T, El-Benna J, Dang PM, Pascolo S, Gougerot-Pocidalo MA, Raposo G, Seabra MC, Amigorena S. Rab27a regulates phagosomal pH and NADPH oxidase recruitment to dendritic cell phagosomes. Nat Cell Biol. 2007;9:367–78.View ArticlePubMedGoogle Scholar
  76. Oberstein TJ, Spitzer P, Klafki HW, Linning P, Neff F, Knolker HJ, Lewczuk P, Wiltfang J, Kornhuber J, Maler JM. Astrocytes and microglia but not neurons preferentially generate N-terminally truncated Abeta peptides. Neurobiol Dis. 2015;73:24–35.View ArticlePubMedGoogle Scholar
  77. Sehlin D, Sollvander S, Paulie S, Brundin R, Ingelsson M, Lannfelt L, Pettersson FE, Englund H. Interference from heterophilic antibodies in amyloid-beta oligomer ELISAs. J Alzheimers Dis. 2010;21:1295–301.PubMedGoogle Scholar
  78. Magnusson K, Sehlin D, Syvanen S, Svedberg MM, Philipson O, Soderberg L, Tegerstedt K, Holmquist M, Gellerfors P, Tolmachev V, et al. Specific uptake of an amyloid-beta protofibril-binding antibody-tracer in AbetaPP transgenic mouse brain. J Alzheimers Dis. 2013;37:29–40.PubMedGoogle Scholar
  79. Sollvander S, Ekholm-Pettersson F, Brundin RM, Westman G, Kilander L, Paulie S, Lannfelt L, Sehlin D. Increased Number of Plasma B Cells Producing Autoantibodies Against Abeta42 Protofibrils in Alzheimer’s Disease. J Alzheimers Dis. 2015;48:63–72.View ArticlePubMedGoogle Scholar
  80. Davis AA, Temple S. A self-renewing multipotential stem cell in embryonic rat cerebral cortex. Nature. 1994;372:263–6.View ArticlePubMedGoogle Scholar
  81. Ravin R, Hoeppner DJ, Munno DM, Carmel L, Sullivan J, Levitt DL, Miller JL, Athaide C, Panchision DM, McKay RD. Potency and fate specification in CNS stem cell populations in vitro. Cell Stem Cell. 2008;3:670–80.View ArticlePubMedGoogle Scholar
  82. Lord A, Philipson O, Klingstedt T, Westermark G, Hammarstrom P, Nilsson KP, Nilsson LN. Observations in APP bitransgenic mice suggest that diffuse and compact plaques form via independent processes in Alzheimer’s disease. Am J Pathol. 2011;178:2286–98.View ArticlePubMedPubMed CentralGoogle Scholar
  83. Stenh C, Englund H, Lord A, Johansson AS, Almeida CG, Gellerfors P, Greengard P, Gouras GK, Lannfelt L, Nilsson LN. Amyloid-beta oligomers are inefficiently measured by enzyme-linked immunosorbent assay. Ann Neurol. 2005;58:147–50.View ArticlePubMedGoogle Scholar

Copyright

© Söllvander et al. 2016

Advertisement

Molecular Neurodegeneration

ISSN: 1750-1326